Rheumatology key messagesOverall TNFi use was not associated with subsequent rates of joint replacement.Among elderly patients, TNFi use was associated with a 40% reduction in subsequent THR rates.Given prior ecological data, future studies are needed to confirm and/or further elucidate the relationship between TNFi and joint replacement.

Introduction
============

Rheumatoid arthritis (RA) is a chronic autoimmune disease driven by pathological inflammatory processes in patients' joints, subsequent hallmarks of which include structural damage to cartilage and bone \[[@key424-B1]\]. Joint damage is a central feature of RA and has been estimated to account for ∼25% of disability in established disease \[[@key424-B4]\]. The permanent and often progressive nature of joint damage, in conjunction with associated pain, loss of function and failure to adequately respond to therapeutic options are strong indications for eventual joint replacement surgery \[[@key424-B5], [@key424-B6]\]. Outcomes for hip and knee replacement in RA are generally considered good \[[@key424-B7]\], although it has been observed that such patients are at increased risk of various adverse events compared with patients undergoing these procedures for osteoarthritis, including dislocation, infection, myocardial infarction and revision \[[@key424-B8], [@key424-B9]\]. Furthermore, there are significant healthcare costs, which in the UK are ∼£6000 -- £7000 per operation \[[@key424-B10]\]. The prevention of irreversible joint damage through early and aggressive management using pharmacotherapy has been well demonstrated and is therefore recommended in numerous national guidelines \[[@key424-B11]\]. First-line therapy options include various conventional synthetic DMARDs (csDMARDs).

Over recent decades, the emergence of biologic therapies such as TNF inhibitors (TNFi) has revolutionized the management of RA as these drugs are widely recognized to improve numerous outcomes of the disease, including joint damage \[[@key424-B14], [@key424-B15]\]. Despite this, to our knowledge there are no randomised controlled trials (RCT) studies addressing the issue of whether biologic therapies prevent/delay ultimate joint failure, as indicated by the need for a joint replacement. Recent ecological data from the UK and Denmark have indicated a reduction in the incidence of knee replacement among RA patients following the introduction of TNFi in 2002/2003 \[[@key424-B16], [@key424-B17]\], however concurrent to this has been an increasing emphasis on early and more aggressive usage of csDMARDs. Patient-level data on this topic is required to disentangle these issues, yet such data remain scarce.

Our current aim was to estimate the comparative effectiveness of TNFi *vs* csDMARDs on subsequent rates of total hip replacement (THR) and total knee replacement (TKR) among a large cohort of RA patients.

Methods
=======

Data sources and exposures
--------------------------

We obtained data from the British Society for Rheumatology Biologics Register for RA (BSRBR-RA). This register contains prospectively collected observational data on over 20 000 RA patients recruited from 2001 onwards, primarily in order to evaluate the real-world safety of TNFi. The initial UK national institute for health and care excellence (NICE) guidance on use of TNFi stipulated clinicians initiating such therapy must register the patient into the BSRBR-RA, and recruitment continued originally until the target of at least 4000 patients per TNFi cohort (etanercept, infliximab or adalimumab) was reached (last 'original' patient recruited 2008) but reopened recruitment to these three originator drugs from 2010 onwards. NICE guidance restricts National Health Service prescribing of TNFi to patients with a sustained 28-joint DAS (DAS28) \>5.1 who have failed to adequately respond to two csDMARDs, with each treatment lasting ⩾6 months. The BSRBR-RA contains an additional comparator cohort of non-biologic treated RA patients on csDMARDs, entry into which was dependent on having active disease (guide DAS28 \> 4.2). Recruitment to this cohort closed in 2008.

Participants in all study cohorts are followed up indefinitely using physician questionnaires sent from BSRBR-RA to the patients' rheumatology clinic. These were sent every six months for a patients' first three years of follow-up, and annually thereafter. In addition to collecting data on changes to therapy and disease details, physicians were asked what serious/adverse events had occurred since the last follow-up date. In addition, patients were asked to complete a health diary every six months for the first three years in the study in which they detailed any hospital admissions. These free text responses were coded by BSRBR-RA staff using the MedDRA hierarchy (Medical Dictionary for Regulatory Activities \[[@key424-B18]\]). Mortality data for participants were obtained from the Health and Social Care Information Centre (now merged into NHS digital) via alerts generated from Office for National Statistics records. The BSRBR has ethical approval from the North West Multicentre Research Ethics Committee (reference number MREC 00/08/053) and patients gave written informed consent to participate in the BSRBR; no further ethical approvals were required to undertake this analysis.

Outcomes
--------

The primary outcomes of interest were first occurrence of THR or TKR, analysed separately. Patients were followed up from date of registration into BSRBR-RA until the earliest date of either outcome event, follow-up form date indicating change in TNFi exposure status (stopping among TNFi users or starting biologics among csDMARD users), last follow-up form or death. Other joint replacement (OJR) (a composite outcome consisting of elbow, shoulder, hand or other small joint replacement) was a secondary outcome.

Study population
----------------

Our study sample ([Supplementary File 1](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* online) consisted of all biologic-naïve RA patients, either in the control cohort or those initiating a TNFi (etanercept, infliximab or adalimumab) no more than 6 months prior to registration within BSRBR-RA. Patients with a THR or TKR recorded prior to registration were excluded, as were patients with \<6 months of follow-up (i.e. those who did not return at least one follow-up questionnaire). In analyses of OJR, further exclusion was made of patients who had undergone an OJR prior to baseline.

Statistical analysis
--------------------

Owing to confounding by indication, i.e. TNFi users *vs* csDMARD users likely having a different baseline risk of THR/TKR, we decided *a priori* to match TNFi users to csDMARD users based on their propensity for receiving treatment. Propensity scores (PS), i.e. the probability of receiving treatment conditional on observed baseline characteristics (including those predictive of outcome) were estimated for all patients using logistic regression. The list of potential confounders included in the PS equation (and described in [Table 1](#key424-T1){ref-type="table"}) consisted of: age, gender, ethnicity, index of multiple deprivation (socio-economic status), BMI, smoking status, year of registration (quintiles), time since RA diagnosis, DAS28, HAQ score, quality of life (SF36 domains), 1987 ACR criteria, systemic involvement, co-morbidities and co-medications. A full description of these variables are included in [Supplementary File 2](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* online. We matched each TNFi patient to the csDMARD patient with the most similar PS within a caliper distance of 0.2 standard deviations of the logit of the PS \[[@key424-B19]\]. Patients falling outside this common support region remained unmatched and were excluded from further analysis. We used matching with replacement \[[@key424-B20]\] owing to fewer available csDMARD patients than TNFi users in the register. Missing data were imputed using chained equations and 10 imputed datasets were created. Statistical analyses were carried out in Stata 15.1 and R.

###### 

Baseline characteristics of propensity score matched cohorts[^a^](#tblfn1){ref-type="table-fn"}: stratified by use of TNFi *vs* conventional synthetic DMARDs

                                                                          CS-DMARD (*n* = 9558) (1644 unique patients)   TNFi (*n* = 9558)                 
  ---------------------------------------------------------------------- ---------------------------------------------- ------------------- ------- ------ -------
  Age, mean ([s]{.smallcaps}.[d]{.smallcaps}.)                                            55.2 (12.1)                       55.2 (12.3)        0           
  Gender: female, %                                                                           7289                             76.3          7259    75.9   −0.01
  Ethnicity: white/Caucasian, %                                                               9114                             95.4          9118    95.4   0.00
  Index multiple deprivation                                                                                                                               
  Quintile 1                                                                                  1282                             13.4          1322    13.8   0.01
  Quintile 2                                                                                  1420                             14.9          1485    15.5   0.02
  Quintile 3                                                                                  1413                             14.8          1640    17.2   0.07
  Quintile 4                                                                                  1544                             16.2          1710    17.9   0.05
  Quintile 5                                                                                  1284                             13.4          1650    17.3   0.11
  Unknown                                                                                     2615                             27.4          1751    18.3   −0.22
  BMI                                                                                      26.8 (5.9)                       27.1 (6.3)       0.06          
  Smoking?                                                                                                                                                 
  \% Current                                                                                  2448                             25.6          2259    23.6   −0.05
  \% Ex                                                                                       3272                             34.2          3577    37.4   0.07
  Calendar period of registration                                                                                                                          
  Oct 01--Oct 03                                                                              1481                             15.5          2262    23.7   0.21
  Nov 03--Aug 04                                                                              2037                             21.3          2037    21.3     0
  Sept 04--Aug 05                                                                             1823                             19.1          1802    18.9   −0.01
  Aug 05--May 07                                                                              1664                             17.4          1462    15.3   −0.06
  May 07--May 16                                                                              2553                             26.7          1995    20.9   −0.14
  Years since diagnosis, median (IQR)                                                     10.8 (10.7)                       11.0 (8.8)       0.02          
  DAS 28, mean ([s]{.smallcaps}.[d]{.smallcaps}.)                                         6.47 (1.09)                       6.43 (0.98)      −0.04         
  Overall HAQ score                                                                       1.91 (0.63)                       1.91 (0.62)      −0.01         
  ACR: ever rheumatoid positive, %                                                            5532                             57.9          6055    63.4   0.11
  ACR deformity of ≥3 joint areas?, %                                                         7425                             77.7          8118    84.9   0.19
  ACR: erosions on hands/feet, %                                                              4651                             48.7          5282    55.3   0.13
  ACR: ever had nodules, %                                                                    4034                             42.2          3988    41.7   −0.01
  ACR: symmetry, %                                                                            7468                             78.1          7883    82.5   0.11
  ACR: deformity of hand joint, %                                                             6771                             70.8          7602    79.5   0.20
  ACR: morning stiffness \>1 h, %                                                             8901                             93.1          8966    93.8   0.03
  Non-major prior joint replacement[^b^](#tblfn2){ref-type="table-fn"}                        1742                             18.2          1989    20.8   0.07

Results shown are for the 10th imputed dataset. Matching was performed using replacement of the cs-DMARD users. 9558 biologic users were each matched to one of the 3229 cs-DMARD users (with replacement). Number of csDMARD patients represented in final matched sample was 1644.

Composite variable consisting of: shoulder, elbow, neck or other small joint replacement (e.g. hand).

SMD: standardized mean difference (smaller values indicative of better balance).

Baseline characteristics of the TNFi user and csDMARD cohorts were summarized and differences assessed by way of standardized mean differences \[[@key424-B21], [@key424-B22]\], with smaller values indicative of greater similarity between cohorts. This assessment was carried out for the cohort prior to matching and in the 10th imputed dataset. Incidence rates of each outcome event with 95% CIs were calculated among matched TNFi users and csDMARD users. Weighted Cox regression was used to compare THR, TKR and OJR rates, taking into account the number of times each individual csDMARD user was included by the matching with replacement, and adjusting the standard error of the estimates accordingly. We censored all patients at 12 years due to the small and unstable size of the csDMARD cohort after this time. Baseline characteristics that were not sufficiently similar post-matching, defined as standardized mean difference \>0.1 (21), were entered into a final multivariable Cox model for further adjustment \[[@key424-B23]\]. Final models were run for all 10 datasets created in the multiple imputation process and hazard ratios (HRs) were pooled using Rubin's rules.

Age and disease severity were *a priori* specified as potential effect modifiers of the association between TNFi use and subsequent need for joint replacement. We tested for these by including interaction terms for approximately median age (\</⩾60 years old) and DAS28 (⩽/\>5.1 NICE cut-off) in the weighted Cox model and used the likelihood ratio test to assess model fit. In the event of a significant interaction (*P \< 0*.1), matching and survival models were re-run stratified by the significant effect modifier.

Sensitivity analyses
--------------------

We addressed the potential of unobserved confounding through the use of an instrumental variable (IV) approach, using physician preference as the instrument, as has been done previously \[[@key424-B24], [@key424-B25]\]. Details of this sensitivity analysis are described in [Supplementary File 3](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* online. We also repeated the main PS analysis after excluding TNFi users recruited into the registry after the csDMARD cohort had closed, in order to maximize comparability between groups.

Results
=======

Of 13 126 eligible RA patients identified in BSRBR-RA, 97% (9558) of the TNFi users and 51% (1644) of the csDMARD users were retained following PS matching ([Supplementary File 1](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* online). Given the 1:1 matching with replacement, a total of 19 116 patient records were used in subsequent analyses, with each csDMARD user being used a median of three (interquartile range (IQR): 1--6) times.

Baseline characteristics of TNFi users were markedly different in the unmatched study sample compared with the csDMARD cohort ([Supplementary File 2](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* online), especially in aspects of disease severity. Specifically, the TNFi cohort had on average higher DAS28, HAQ score, proportion fulfilling the 1987 ACR RA criteria, lower health-related quality of life (as per SF36), longer disease duration and a higher prevalence of prior non-major joint replacement. Conversely, baseline characteristics between exposure cohorts were much more similar post-matching ([Table 1](#key424-T1){ref-type="table"}). The only persisting differences (standardized mean difference \> 0.1) between the matched cohorts were calendar period of registration, low deprivation and the proportion of patients fulfilling ACR criteria.

Total hip replacement
---------------------

A total of 589 THRs were reported during follow-up (median = 4.94 years \[IQR: 1.52--10.04\] for TNFi and 5.97 years \[IQR: 2.05--9.55\] for csDMARD) of the propensity-matched cohorts. Incidence rates (per 1000 PYs) were 5.22 \[95% CI: 4.66, 5.88\] and 6.30 (95% CI: 4.24, 9.76) among TNFi users and csDMARD users, respectively ([Supplementary File 4](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* online).

Comparing TNFi to csDMARDs yielded a pooled HR = 0.91 \[95% CI: 0.64, 1.31; *P = 0*.62\], which when adjusted for any remaining post-matching imbalance in baseline covariates was 0.86 \[95% CI: 0.60, 1.22; *P = 0*.39\] ([Fig. 1](#key424-F1){ref-type="fig"}).
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Total knee replacement
----------------------

Among the matched sample, a total of 864 TKRs were reported during followup (median = 4.85 years \[IQR: 1.50--10.01\] for TNFi and 5.98 years \[IQR: 2.03--9.55\] for csDMARD) of the propensity-matched cohorts. Incidence rates (per 1000 PYs) were 8.89 \[95% CI: 8.13, 9.72\] and 8.09 \[95% CI: 5.32, 12.89\] among TNFi users and csDMARD users, respectively ([Supplementary File 4](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* online). This yielded a pooled HR = 1.18 \[95% CI: 0.90, 1.56; *P = 0*.24\], which when adjusted for any remaining post-matching imbalance in baseline covariates was 1.11 \[95% CI: 0.84, 1.47; *P = 0*.46\] ([Fig. 1](#key424-F1){ref-type="fig"}).

Other joint replacement
-----------------------

Among the matched sample, a total of 336 OJRs occurred during follow-up (median = 4.93 years \[IQR: 1.52--10.02\] for TNFi and 5.98 years \[IQR: 2.05--9.12\] for csDMARD) among the propensity-matched cohorts. Incidence rates (per 1000 PYs) were 4.34 \[95% CI: 3.76, 5.02\] and 3.87 \[95% CI: 1.97, 8.73\] among TNFi and csDMARD users, respectively ([Supplementary File 4](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* online). There was no significant difference in OJR rates between the exposure cohorts ([Fig. 1](#key424-F1){ref-type="fig"})

Interactions
------------

Age was found to be a significant (*P \< 0*.001) effect modifier for both THR and TKR outcomes, although disease severity was not (*P \> 0*.1). In subsequent stratified analyses ([Supplementary File 5](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* online), TNFi was associated with an estimated 40% reduction in incidence of THR among older patients (HR = 0.60 \[95% CI: 0.41, 0.87; *P = 0*.008\]) ([Fig. 2](#key424-F2){ref-type="fig"}). Differences in THR or TKR incidence rates between TNFi and csDMARD cohorts among younger patients were non-significant ([Fig. 2](#key424-F2){ref-type="fig"}, [Supplementary File 5](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* online).

![Estimated impact of TNFi on subsequent joint replacement rates among matched TNFi and csDMARD patients: stratified by age\
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Sensitivity analyses
--------------------

Results were unchanged when PS matching and subsequent survival analysis was repeated following exclusion of (*n* = 1213) patients recruited into the TNFi cohort after the csDMARD cohort had closed. Comparative effectiveness estimates were HR = 0.81 (95% CI: 0.55, 1.18) for THR and 1.11 (95% CI: 0.83, 1.50) for TKR. Results of the sensitivity IV analysis ([Supplementary Files 6 & 7](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* online) confirmed main findings, with a borderline reduction in risk of THR (absolute risk reduction of --1.88 per 100 patients \[95% CI: --3.86, 0.10; *P = 0*.063\]) but no association between biologics use and TKR risk (--0.57 per 100 patients \[95% CI: --2.69, 1.54; *P = 0*.60\]).

Discussion
==========

Main findings
-------------

We have sought to address the scarcity of patient-level data comparing use of TNFi *vs* csDMARDs on rates of joint replacement in RA. Using a large UK-based RA biologics register, overall we found no difference in subsequent rates of joint replacement between PS matched TNFi and csDMARD users. When stratified by age, TNFi was associated with a significant 40% reduction (*P = 0*.008) in THR incidence among patients ⩾60 years old ([Fig. 2](#key424-F2){ref-type="fig"}), although non-significant increases were observed in TKR for the same age group and in THR for those \<60 years old.

Findings in context
-------------------

Our overall incidence rates of THR and TKR (results not shown) of 4.95/1000 PYs and 7.84/1000 PYs, respectively, align well with previous estimates of joint replacement among RA patients within the UK \[[@key424-B16]\] and elsewhere \[[@key424-B17], [@key424-B26], [@key424-B27]\].

Emerging observational data indicate that the number and/or incidence of RA-related joint surgery has been in decline across numerous developed countries \[[@key424-B16], [@key424-B17], [@key424-B27]\], although this has primarily been seen for smaller joints \[[@key424-B35], [@key424-B37]\]. Many of these studies have inferred a possible role of biologics in this decline. Indeed, a reduction in need for joint replacement associated with TNFi use would be an expected finding given previous evidence of TNFi use reducing joint damage as measured radiographically \[[@key424-B15]\]. A previous meta-analysis of 70 RCT studies reported that annual radiographic progression was 0.6% less in patients treated with biologics compared with those on a single DMARD \[[@key424-B40]\]. Similarly, another meta-analysis has demonstrated that patients on initial combination therapy (methotrexate plus a biologic agent) are 30% more likely to experience non-progression at 1-year than those on methotrexate alone \[[@key424-B41]\]. In this context, a 40% reduction in THR rates associated with TNFi use among a more elderly subgroup of patients as found in the present study is quite plausible, and a lack of translation of positive findings on joint erosion from prior RCTs into a 'real world' reduction in rates of joint replacement within our main study sample is initially surprising.

However, a more detailed examination of prior RCT findings indicate that an expectation of widespread reduction in joint replacement associated with TNFi use is potentially unwarranted. There is a large degree of variation in the nature of comparator groups used in prior studies \[[@key424-B42], [@key424-B43]\], and this could be an important factor in considering the lack of effect as described in our main findings. For instance, while RCT studies have shown reduced radiographic progression among biologic users *vs* csDMARD monotherapy, an almost equal reduction has been achieved among combination csDMARD users relative to csDMARD monotherapy \[[@key424-B40]\]. Similarly, while TNFi has been shown to confer early benefits over combination csDMARD therapy, these benefits have been reported to disappear during the second year of follow-up \[[@key424-B44]\], possibly due to time-to-efficacy and time to achieve maximal dose of csDMARDs. The use of etanercept (*vs* oral triple therapy) resulted in only small radiographic benefits in another trial \[[@key424-B45]\], with another showing triple therapy to be non-inferior to biologics in terms of change in DAS28 at 48 weeks \[[@key424-B46]\]. Given these previous data, it could be that the reduced THR rates in older patients may reflect a general improvement in management of RA over the past 20 years and earlier and more aggressive use of csDMARDs rather than solely the effect of TNFi. Intriguingly, a registry-based study on the topic \[[@key424-B47]\] recently found increased rates of major joint replacement associated with use of biologic therapy, although the authors concluded residual confounding was an issue given the small number of confounding factors for which the analysis was adjusted.

We found a reduction in THR incidence among an older patient subgroup, but no significant impact on TKR incidence, which is interesting as one might expect any effect to be expressed approximately equally at hip and knee. It could be that the relatively long disease duration at our baseline meant there was greater potential for prevention of joint destruction at the hip over knee, although details of differential natural history of RA disease at these two joints are not well established. It is also very difficult to disentangle the impact of TNFi on improved function and overall quality of life and how this may have mediated effects on longer-term progression of joint damage, potentially differentially at the knee and hip. Another factor could be the role of trauma related THRs among the older subgroup and whether there may be some pathway to reduced THR rates via TNFi associated improvement in bone quality. It should be emphasized, however, that the positive impact on THR incidence was only observed in a subgroup of patients that have not been well studied in this regard previously and that prior studies at the population-level have identified different patterns in this regard, some finding reduced rates of TKR \[[@key424-B16], [@key424-B17]\] and others THR \[[@key424-B27], [@key424-B34]\] following introduction of TNFi

Limitations
-----------

The potential for residual confounding by indication is a key limitation of the current study. Given that prior to matching there was a much higher disease severity among the TNFi group ([Supplementary File 2](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* online), we cannot rule out that the overall lack of reduction in joint replacement rates among TNFi users may be due in part to a greater prevalence of unmeasured aspects of disease severity and unresponsiveness to therapy in this group, thereby maintaining a baseline 'disadvantage' even after PS matching. On the other hand, estimates of the impact of TNFi exposure may be subject to a general healthy user bias in that a clinician perceives sufficient patient ability to tolerate and benefit from more intensive therapy regimens, which may have here contributed to the reduced rate of THR in the older TNFi cohort. The use of an IV approach as a sensitivity analysis sought to address the issue of unmeasured confounding, in which the treatment effect was estimated using clinician preference for biologics as an IV, assuming this to be a strong predictor of exposure but unrelated/weakly-related to confounders of the TNFi--joint replacement relationship. However, the findings of this IV approach should be interpreted with caution given the instrument was here associated with several measured confounders ([Supplementary File 3](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* online) which may undermine its validity as a means to obtain unbiased estimates in the presence of unmeasured confounding. The PS analytical approach taken, in which comparable csDMARD matches were found for each TNFi user---while much improving the internal validity---does mean our findings are not average treatment effects generalizable to the entire RA population but an estimate of the 'average treatment effect on the treated' \[[@key424-B48]\]. This is evident given that the csDMARD users included in the matched sample had more established and severe disease (thereby making them comparable to the TNFi sample) than the unmatched csDMARD sample ([Supplementary File 2](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* online). The study findings should also be interpreted in the context of a relatively long median disease duration at baseline ([Table 1](#key424-T1){ref-type="table"}), which means they are not necessarily generalizable to the context of early RA. Finally, we relied on a combination of physician-reported and self-reported incidence of THR, TKR and OJR for our study outcomes as per BSRBR-RA follow-up questionnaires. This may have introduced bias if events were under-reported, although this would likely act non-differentially in regard to TNFi status and minimally during the early years of follow-up, during which time study participants were sent questionnaires every six months. These various limitations to the present analysis may partly explain differences in the results obtained here compared with previous ecological data on widespread reductions in joint replacement rates in RA during the biologic era. While a reduction in THR amongst older TNFi users offers some support for biologics playing a role in reducing need for joint replacement, it must also be noted that the lack of an overall protective effect is suggestive that other factors apart from TNFi are likely to be involved in the aforementioned downward population trends in joint replacement rates in RA.

Strengths
---------

Our study's key strengths are that BSRBR-RA is one of the largest RA registers in the world, which made it possible for us to adjust for many potential confounders and stratify analyses where there was significant effect modification. We were also able to accurately censor follow-up given the linkage to Health and Social Care Information Centre mortality data. The use of PS matching is a strong method for dealing with bias \[[@key424-B19]\] arising from likely confounding by TNFi indication, and we were able to reach good balance between the two exposure groups in terms of baseline characteristics across most variables.

Conclusion
----------

In this large prospective study, we found no overall association between TNFi *vs* csDMARD therapy and subsequent incidence of joint replacement among RA patients, although a 40% relative reduction in THR rates was found among older patients. Future studies are needed to confirm and/or further elucidate the relationship between TNFi use and joint replacement.

Supplementary Material
======================

###### 

Click here for additional data file.
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